Literature DB >> 17908631

Are we improving the long-term burden of Hodgkin's lymphoma patients with modern treatment?

Berthe M P Aleman1, Flora E van Leeuwen.   

Abstract

The cure rate of patients who have Hodgkin's lymphoma (HL) amounts to 80% or more because of risk-adapted treatment using modern chemotherapy and radiotherapy schedules. In this article we describe important late effects after treatment of HL and how we expect the long-term burden of patients who have HL to change applying modern treatments. Because treatment always has side effects to some extent, awareness of possible late effects after treatment remains important for patients and treating physicians.

Entities:  

Mesh:

Year:  2007        PMID: 17908631     DOI: 10.1016/j.hoc.2007.07.005

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  5 in total

1.  Cumulative morbidity and late mortality in long-term survivors of exocrine pancreas cancer.

Authors:  Nisha L Jacobs; Florencia G Que; Robert C Miller; Santhi Swaroop Vege; Michael B Farnell; Aminah Jatoi
Journal:  J Gastrointest Cancer       Date:  2009

2.  Long-term hospitalisation rates among 5-year survivors of Hodgkin lymphoma in adolescence or young adulthood: A nationwide cohort study.

Authors:  Kathrine Rugbjerg; Maja Maraldo; Marianne C Aznar; David J Cutter; Sarah C Darby; Lena Specht; Jørgen H Olsen
Journal:  Int J Cancer       Date:  2017-03-14       Impact factor: 7.396

3.  International development of four EORTC disease-specific quality of life questionnaires for patients with Hodgkin lymphoma, high- and low-grade non-Hodgkin lymphoma and chronic lymphocytic leukaemia.

Authors:  Lonneke van de Poll-Franse; Simone Oerlemans; Anne Bredart; Charalampia Kyriakou; Monika Sztankay; Stephan Pallua; Laurien Daniëls; Carien L Creutzberg; Kim Cocks; Sandra Malak; Giovanni Caocci; Stefano Molica; Weichu Chie; Fabio Efficace
Journal:  Qual Life Res       Date:  2017-11-10       Impact factor: 4.147

4.  Vera Peters and the curability of Hodgkin disease.

Authors:  D H Cowan
Journal:  Curr Oncol       Date:  2008-10       Impact factor: 3.677

5.  Light therapy as a treatment of cancer-related fatigue in (non-)Hodgkin lymphoma survivors (SPARKLE trial): study protocol of a multicenter randomized controlled trial.

Authors:  Daniëlle E J Starreveld; Laurien A Daniels; Heiddis B Valdimarsdottir; William H Redd; Jessie L de Geus; Sonia Ancoli-Israel; Susan Lutgendorf; Catharina M Korse; Jacobien M Kieffer; Flora E van Leeuwen; Eveline M A Bleiker
Journal:  BMC Cancer       Date:  2018-09-10       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.